Marina Biotech closes RNAi research site in Cambridge, MA; Gilead takes heat from AIDS advocates for Truvada effort;

@FierceBiotech: Gates Foundation investing in biomarker research to aid TB diagnosis in developing countries. Release | Follow @FierceBiotech

@JohnCFierce: Gilman's Stromedix snagged by Biogen for $75M upfront, $487M in milestones. Release | Follow @JohnCFierce

@RyanMFierce: Novartis' MS pill showed promise in a mouse study for treating Lou Gehrig's. ALS patients will line up for PhI. Article | Follow @RyanMFierce

@FierceMedDev: FDA: New Jersey company agrees to halt production of unapproved dental devices. Release | Follow @FierceMedDev

@MarkHFierce: Radiation treatments can transform breast cancer cells into treatment-resistant breast cancer stem cells. Fascinating. Release | Follow @MarkHFierce

> Bothell, WA-based RNAi drug researcher Marina Biotech ($MRNA) has shuttered its Cambridge, MA, operation, affecting workers who joined the company through its acquisition of Cequent Pharmaceuticals. Marina release

> The FDA has granted priority review to Gilead Science's ($GILD) drug Truvada as a protective treatment for patients at risk of HIV infection, while an AIDS group has given thumbs down to the California biotech's effort to gain the additional approval of the drug. Item

> The Baupost Group, a Boston investment fund, has acquired an 18% stake in Winston-Salem, NC-based drug developer Targacept, according to a recent regulatory filing. Report

Pharma News

@FiercePharma: Obama budget doesn't just have more industry money for FDA. Higher Medicare/Medicaid rebates, too. $156B worth, in fact. Report | Follow @FiercePharma

> Obama budget digs deep into pharma's wallet. Item

> Pharma remains heartburn HQ as 44% fear job loss. Story

> Greek pharma cuts amount to $1.3B. Report

> Hospira's quality issues weigh on Q4 results, 2012 forecast. News

Research News

> Drug briefly reversed Huntington's-related motor skills decline. News

> Obama seeks $156M to boost Alzheimer's research through 2013. Item

> Key protein appears to kill off HIV food supply in certain cells. Story

> Curcumin, in Indian curry spice, may beat down prostate tumors. More

> Umbilical cord stem cells may restore infants' hearing. Article

Manufacturing News

> Federal charges filed against Dallas compounding pharmacy. Story

> South Africa, Lonza partner on $210 million API facility. News

> Ben Venue can't say when crucial cancer drug will be available. Piece

> Dramatic decrease in pharma cargo thefts seen in 2011. Report

> Hospira beefs up quality management team. Article

> FDA asks heparin makers to test APIs for contaminants, including BSE. Item

And Finally... A Cincinnati, OH, biotech incubator has shut its doors completely after saying it would try to stay open for business development and other services for fledgling life sciences ventures. Article

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.